Title:	**A randomized open label, two treatments, two periods, two sequences, single dose, bioequivalence study of *Domperidone 10mg* tablet of Amin Pharm Co., IRAN and *Motilium® 10mg* tablet of Janssen, in 24 healthy adult subjects under fasting conditions**
Sponsor:	AMIN Pharm Co., IRAN
Investigational Products:	- Domperidone 10mg tablet - Amin Pharm Co. - Motilium® 10mg tablet - Janssen
Principle Investigator:	Ladan Tayebi
Clinical:	Core Research Lab. Of Zahedan University of Medical Sciences
Executive Colleagues:	H. Ghaznavi; Z. Ayesteh; Sh. Bohlooli
Bio-Analytical Pharmacok. & Statistics:	- Pars Biopharmacy Research Lab. - Nik Azma Pars Alborz Lab.
No. of Subjects:	24 healthy adult subjects
Regimen & Duration of Treatment:	- A single dose of 2*10 mg domperidone tablet - Washout period: At least 7 days
Blood Sampling Points:	Before and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 24.0 and 48.0 hours post-dose.
Criteria for Evaluation:	- Efficacy: AUC_{0-48}, $AUC_{0-\infty}$, C_{max}, T_{max}, K_e and $T_{1/2}$ - Safety: Adverse events
Criteria for Bioequivalence:	90% Confidence Intervals of Log-transform data of ratio (T/R)
Conclusion:	- Both formulations had no Serious Adverse Events - The 90% confidence intervals calculated for Log-Transformed data of AUC_{0-48} and C_{max} values were within the limits of 90 – 110%.
	
Final Report Date:	Feb. 2025
This study was approved by Iran Food and Drug Administration	